Salim Jaffer, MD
Gastroenterology · Goshen, INNPI 1043387566
Payments from drug & device makers
What this record shows
This record is dominated by other: $20,855 of the $25,390 with a category attached, or 82.1%. Olympus America Inc. accounts for 82.1% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2021 at $21,389 and has fallen 98.3% since, to $373 in 2025. Among gastroenterology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 286 payments — averaging $88.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$21K
- AbbVie$2K
- Johnson & Johnson$473
- Takeda Pharmaceuticals U.S.A., Inc.$426
- Regeneron Healthcare Solutions, Inc.$264
- Nestle Healthcare Nutrition Inc.$261
- plus $1K from 23 others
What the payments were for
- Food & beverage$4,41217%
- Education$700%
- Gifts$530%
- Other$20,85582%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 1 | $20,855 |
| AbbVie | 110 | $1,733 |
| Johnson & Johnson(2 entities) | 27 | $473 |
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $426 |
| Regeneron Healthcare Solutions, Inc. | 12 | $264 |
| Nestle Healthcare Nutrition Inc. | 23 | $261 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 21 | $248 |
| Gilead | 10 | $182 |
| Braintree Laboratories, Inc. | 9 | $142 |
| Sanofi | 5 | $99 |
| UCB, Inc. | 5 | $94 |
| Ardelyx, Inc. | 4 | $90 |
| Intercept Pharmaceuticals, Inc. | 4 | $83 |
| Ferring Pharmaceuticals Inc. | 4 | $64 |
| Pfizer | 4 | $59 |
| QOL Medical, LLC | 3 | $54 |
| Boehringer Ingelheim | 2 | $40 |
| AstraZeneca | 2 | $36 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Shionogi Inc | 1 | $23 |
| Bristol Myers Squibb | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Micro-tech Endoscopy USA, Inc. | 1 | $5 |
How this compares
$25,390 in reported general payments places this provider in the 90th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Omeprazole | 127 | $1,327 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 28 | $529 |
| Esomeprazole Magnesium | 17 | $431 |
| Pantoprazole Sodium | 16 | $84 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Goshen
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Jonathan ObertNew Albany$302K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Matthew BohmWestfield$239K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Anoop AppannagariMunster$120K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.